 Submitted By Gary Tanashian
Gold, silver, oil, Euro... they're all vehicles for people who look at Uncle Buck - slumped and hung over with a mess in his shorts - and scream 'RUN AWAY!!!'...
|
Submitted By Gary Tanashian
Paul,
USU Q3 profit more than triples & Centrifuge still on trackThis goes nicely with the Korean Utility contract
This blogger would like to thank you for the email that alerted me to this opportunity to buy other people's angst at near rock bottom prices...
|
 Submitted By Tom Lydon
Everyone has their way of analyzing exchange traded funds (ETFs) for their portfolio. Morningstar analyst Jeffrey Ptak looks at ETFs in a different light than most. He views them as individual stocks, checking fair values of companies within an ETF...
|
Submitted By Gary Tanashian
Markets are falling apart all around and he's back with that cursed airline index again! XAL has not made a lower low and has been an ongoing bearish divergence for oil. Let's see if it keeps up...
|
 Submitted By Faisal Laljee
Garmin's (GRMN) delayed bid for Tele-Atlas confirms investor sentiment that perhaps Navteq (NVT) should have played a little hardball before agreeing to be purchased by Nokia (NOK). I am still disappointed that Navteq gave up so cheaply. They are worth more and I am still holding their shares in...
|
 Submitted By David Templeton
Vectren Corp. (VVC) announced the company will increase its fourth quarter dividend 3.2%. The new quarterly dividend increases to 32.5 cents per share versus 31.5% per share in the same quarter last year. This is the 48th consecutive year the company has increased its annual dividend. The projected...
|
Submitted By Gary Tanashian
I thought I would check up on the monthly XAU cup w/ handle I did back in August, and one look at the current chart says only one thing; BOOLISH...
|
 Submitted By Mike Havrilla
Gauging Risk For Colorectal Cancer Helps To Determine Screening Test...
|
Submitted By Mike Havrilla
1.) Genitope (Nasdaq: GTOP): Clinical trial results for MyVax likely to disappoint.
2.) Favrille (Nasdaq: FVRL): FavId trial likely to fail.
3.) Pharmacyclics (Nasdaq: PCYC): Xcytrin NDA filed under protest with likely rejection by FDA with PDUFA date of 12/31/07.
October 31, 2007...
|
Submitted By Mike Havrilla
A 2-page PDF stock research report for School Specialty (Nasdaq: SCHS) - a possible short sale candidate for aggressive traders.October 31, 2007...
|
Submitted By Cabeza Howe
At this late stage of the China bubble, I’m looking around for great Chinese names with fair valuation. One such name is Tongjitang Chinese Medicines (TCM). Here are some of the reasons I think it will be a winner in the next decade...
|
Submitted By Mike Havrilla
23-Oct-07: The Company announced receipt of notification from The NASDAQ Stock Market LLC® that the Company’s common stock is approved for listing on The NASDAQ Global Market. The Company’s board of directors approved the decision to switch the listing of BioSante’s common stock from The...
|
Submitted By Mike Havrilla
Friday October 26, 11:47 am ET
TORONTO, ONTARIO--(MARKET WIRE)--Oct 26, 2007 -- Crystallex International Corporation (Toronto:KRY.TO - News)(AMEX:KRY -...
|
 Submitted By Turley Muller
I am presenting this analysis in response to discussion on Fat Pitch Financials regarding the recent article "52-week-low-list-packed-with-quality-names" posted by George. Walgreen Company was a topic in the reader comments thread, and curiosity arose as to whether WAG is an attractive buy at...
|
 Submitted By Mark McQueen
A few decades ago, Canada did away with the death penalty. The reasons vary from “inhumane for a modern society” to “what if we put an innocent person to death?”. Why then, with that backdrop, are we arming police forces, campus cops and hospital security staff with Tasers?...
|
|
$5000 Practice Forex Trading Account
Software and live rates provided by FXCM
|
's
